Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Receivables (2022 - 2025)

Zentalis Pharmaceuticals has reported Change in Receivables over the past 3 years, most recently at -$5.0 million for Q1 2025.

  • Quarterly results put Change in Receivables at -$5.0 million for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$5.0 million (down 200.0% YoY), and the annual figure for FY2025 was -$5.0 million, down 200.0%.
  • Change in Receivables for Q1 2025 was -$5.0 million at Zentalis Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for ZNTL hit a ceiling of $5.0 million in Q4 2024 and a floor of -$5.0 million in Q1 2025.
  • Median Change in Receivables over the past 3 years was $4000.0 (2022), compared with a mean of $1333.3.